Ashland reports fourth quarter fiscal 2025 results and issues outlook for full-year 2026

Sales of $478 million, down eight percent from the prior-year quarter previously announced carboxymethylcellulose (cmc), methylcellulose (mc), nutraceuticals and avoca portfolio optimization initiatives (collectively, portfolio optimization) reduced overall sales by approximately $38 million or seven percent versus the prior-year quarter. excluding these initiatives, sales declined one percent income from continuing operations of $33 million, or $0.73 per diluted share adjusted income from continuing operations excluding intangibles amortization expense of $50 million, or $1.08 per diluted share net income of $32 million, or $0.71 per diluted share adjusted ebitda of $119 million, down four percent from the prior-year quarter, with portfolio optimization contributing to a nine percent or $11 million decline.
ASH Ratings Summary
ASH Quant Ranking